EP-104IAR for EoE (RESOLVE Trial)

"As indicated on clinicaltrials.gov, this experiment is in the process of seeking participants. It was first uploaded to the website on March 31st 2023 and has been modified as recently as May 17th 2023."

"According to the data furnished by Eupraxia Pharmaceuticals Inc., this clinical trial's main objective, assessed over a period of 12 weeks, is measuring fluctuations in morning serum cortisol levels. Secondary outcomes recorded include changes from baseline on the Straumann Dysphagia Index (SDI), which gauges dysphagia frequency and intensity via two independent 5-point and 6-point scales; dysphagia severity based on an 11 point Likert scale ranging between 0(no trouble) - 10(most severe); and odynophagia pain relief quantified through another 11 point Likert Scale calibrated from 0(no"

"This study seeks 24 candidates, aged between 18 and 75, suffering from eosinophilic esophagitis. Primary conditions of eligibility are being symptomatic with EoE; for women capable of bearing children, a negative pregnancy test is mandatory in addition to using highly effective contraceptives until the end of the trial; commitment to adhere to all procedures and visit schedule outlined by the research team; willingness to give informed consent."

"The parameters for patient inclusion in this clinical trial necessitate a minimum age of 18 and a maximum age of 75."

"The safety of EP-104IAR 20 mg was rated at 1 due to the limited data available from Phase 1 trials, leaving efficacy and safety yet unconfirmed."

"Those interested in participating are able to choose from 4 different recruitment sites, which include Adelaide, Vancouver and Amsterdam among others. To minimize travel requirements if one is accepted into the trial, we recommend selecting the nearest site for enrollment."

"To begin this medical experiment, 24 volunteers that meet the predetermined inclusion criteria need to be recruited. The research is taking place in multiple locations such as Royal Adelaide Hospital of South Australia and G.I. Research Institute in Vancouver, British Columbia."